Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.918 USD | -0.21% | -5.16% | -34.62% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Analyst Reco.